Impact of Mirabegron on Erectile Function in BPH Patients

Impact of Beta 3 Agonist Mirabegron on Erectile Function on Patients With Benign Prostate Hyperplasia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04503850

Enrollment

100

Registered

2020-08-07

Start date

2020-10-01

Completion date

2021-10-01

Last updated

2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Males With Benign Prostatic Hyperplasia Symptoms

Brief summary

Evaluation of impact of Mirabegron on erectile function for patients treated for BPH

Detailed description

50 patients (Group A) will receive Mirabegron & alpha blocker 50 patients (Group B) will receive alpha blocker only Evaluation using IIEF 5 scoring system

Interventions

DRUGMirabegron 50 MG

Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system

DRUGAlpha Blockers

Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

50 Years to No maximum

Inclusion criteria

* All males above age 50 with LUTS due to BPH not candidate for prostatectomy

Exclusion criteria

* males below age 50 * neurologic abnormality * Any indication for prostatectomy * abnormal bladder contractility i.e diabetics

Design outcomes

Primary

Measure	Time frame	Description
Impact of Mirabegron on erectile function	6 months	Using international index of erectile function 5 score system , least score 5 means severe erectile dysfunction and highest score 25 means no erectile dysfunction

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026